Ariosto S Silva
Overview
Explore the profile of Ariosto S Silva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hasipek M, Grabowski D, Guan Y, Alugubelli R, Tiwari A, Gu X, et al.
Cancers (Basel)
. 2021 Jun;
13(11).
PMID: 34071205
Multiple myeloma is a genetically complex hematologic neoplasia in which malignant plasma cells constantly operate at the maximum limit of their unfolded protein response (UPR) due to a high secretory...
12.
Koomen D, Meads M, Magaletti D, Guingab-Cagmat J, Oliveira P, Fang B, et al.
J Proteome Res
. 2021 May;
20(6):3134-3149.
PMID: 34014671
Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell...
13.
Zhao X, Wang M, Jiang H, Lwin T, Park P, Gao J, et al.
Cell Rep
. 2021 Mar;
34(11):108870.
PMID: 33730585
Ibrutinib, a bruton's tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical...
14.
Sudalagunta P, Silva M, Canevarolo R, Alugubelli R, DeAvila G, Tungesvik A, et al.
EBioMedicine
. 2020 Apr;
54:102716.
PMID: 32268267
Background: Multiagent therapies, due to their ability to delay or overcome resistance, are a hallmark of treatment in multiple myeloma (MM). The growing number of therapeutic options in MM requires...
15.
Zhao X, Ren Y, Lawlor M, Shah B, Park P, Lwin T, et al.
Cancer Cell
. 2019 May;
35(5):752-766.e9.
PMID: 31085176
Drug-tolerant "persister" tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of...
16.
Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, et al.
J Clin Invest
. 2018 Sep;
128(12):5517-5530.
PMID: 30260324
Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL) results in aggressive disease that is refractory to treatment. By integrating activity-based proteomic profiling and drug screens, polo-like kinase-1...
17.
Shah B, Zhao X, Silva A, Shain K, Tao J
Trends Cancer
. 2018 Mar;
4(3):197-206.
PMID: 29506670
Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify...
18.
Maley C, Aktipis A, Graham T, Sottoriva A, Boddy A, Janiszewska M, et al.
Nat Rev Cancer
. 2017 Sep;
17(10):605-619.
PMID: 28912577
Neoplasms change over time through a process of cell-level evolution, driven by genetic and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic cell determines which changes provide...
19.
Ribeiro M, Silva A, Bailey K, Kumar N, Sellers T, Gatenby R, et al.
J Nutr Food Sci
. 2013 Dec;
2:6.
PMID: 24371544
Oral administration of pH buffers can reduce the development of spontaneous and experimental metastases in mice, and has been proposed in clinical trials. Effectiveness of buffer therapy is likely to...
20.
Khin Z, Ribeiro M, Jacobson T, Hazlehurst L, Perez L, Baz R, et al.
Cancer Res
. 2013 Dec;
74(1):56-67.
PMID: 24310398
Accurate preclinical predictions of the clinical efficacy of experimental cancer drugs are highly desired but often haphazard. Such predictions might be improved by incorporating elements of the tumor microenvironment in...